Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
JAMA Network Open · 25.10.2024 · 7 (10) · e2440997
DOI: 10.1001/jamanetworkopen.2024.40997 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.10.2024. Verfasst von Alice Shanklin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Critical Care Medicine, Children's National Hospital, Washington, DC. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Intensive Care Units, Pediatric. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Themen: Intensivpflege
Abstract (Originalsprache)
Importance Bronchiolitis is the most common diagnosis necessitating respiratory support and pediatric intensive care, and respiratory syncytial virus (RSV) is the most common cause of bronchiolitis. In 2023, the monoclonal antibody nirsevimab and the maternal RSVpreF vaccine were implemented to prevent RSV in infants.
Objective
To determine the potential association of novel RSV prevention strategies with pediatric intensive care unit (ICU) utilization. Design, Setting, and Participants This retrospective cross-sectional study examined US pediatric ICU encounters with and without RSV from January 1, 2017, to June 1, 2023. Data were from Oracle Cerner RealWorld Data, a national electronic health record database. All children (aged >1 day and <18 years) admitted to an ICU during the study period were included in the analysis. Statistical analysis was performed from February to May 2024. Main Outcomes and Measures The primary outcomes were ICU encounters with RSV and ICU encounters with RSV eligible for RSV prevention.
Results
There were 119 782 ICU encounters from 53 hospitals; 65 757 encounters (54.9%) were male; median (IQR) age was 4.5 (1.1-12.5) years, median (IQR) ICU length of stay was 1.8 (1.0-3.9) days; 13 702 ICU encounters (11.4%) had RSV, of which 38.6% (5217) were eligible for prevention (4.4% of total ICU encounters). Encounters with RSV accounted for 21.1% (109 334) of ICU days, of which 43.8% (47 888) were eligible for prevention (9.2% of total ICU days). Encounters with RSV were associated with a greater use of positive pressure ventilation (4074 [29.7%] vs 18 821 [17.7%]; P < .001) and vasoactive medications (3057 [22.3%] vs 18 570 [17.5%]; P < .001) compared with those without RSV. Conclusions and Relevance The findings of this retrospective cross-sectional study of RSV and US pediatric intensive care utilization suggest that if 65% to 85% of eligible children received RSV prevention, an estimated 2.1% to 2.8% reduction in pediatric ICU encounters and an estimated 4.5% to 5.9% reduction in pediatric ICU days could be achieved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pediatric Critical Care Medicine, Children's National Hospital, Washington, DC.
- Now with Division of Pediatric Critical Care Medicine, Cohen Children's Medical Center, New York, New York.
- Research Division of Biostatistics and Study Methodology, Children's National Hospital, Washington, DC.
Förderung
- NICHD NIH HHS
Zitieren
APA
Shanklin, A., Olson, T., Patel, A. K., Trujillo Rivera, E. A., & Pollack, M. M. (2024). Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization. JAMA Network Open, 7(10), e2440997. https://doi.org/10.1001/jamanetworkopen.2024.40997
Vancouver
Shanklin A, Olson T, Patel AK, Trujillo Rivera EA, Pollack MM. Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization. JAMA Network Open. 2024;7(10):e2440997. doi:10.1001/jamanetworkopen.2024.40997
BibTeX
@article{Shanklin2024,
author = {Shanklin, Alice and Olson, Taylor and Patel, Anita K and Trujillo Rivera, Eduardo A and Pollack, Murray M},
title = {Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {10},
pages = {e2440997},
doi = {10.1001/jamanetworkopen.2024.40997}
}
EUVIMED